THTX vs. CASI, ACXP, VYNE, IPA, VIRX, NRXP, FBIO, DARE, APRE, and LEXX
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include CASI Pharmaceuticals (CASI), Acurx Pharmaceuticals (ACXP), VYNE Therapeutics (VYNE), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), NRx Pharmaceuticals (NRXP), Fortress Biotech (FBIO), Daré Bioscience (DARE), Aprea Therapeutics (APRE), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical preparations" industry.
Theratechnologies (NASDAQ:THTX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.
Theratechnologies has higher revenue and earnings than CASI Pharmaceuticals. Theratechnologies is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Theratechnologies has a net margin of -23.04% compared to CASI Pharmaceuticals' net margin of -79.30%. Theratechnologies' return on equity of 0.00% beat CASI Pharmaceuticals' return on equity.
CASI Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 391.80%. Given CASI Pharmaceuticals' higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Theratechnologies.
CASI Pharmaceuticals received 170 more outperform votes than Theratechnologies when rated by MarketBeat users. However, 52.73% of users gave Theratechnologies an outperform vote while only 51.69% of users gave CASI Pharmaceuticals an outperform vote.
In the previous week, CASI Pharmaceuticals had 3 more articles in the media than Theratechnologies. MarketBeat recorded 4 mentions for CASI Pharmaceuticals and 1 mentions for Theratechnologies. CASI Pharmaceuticals' average media sentiment score of 0.62 beat Theratechnologies' score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media.
22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
CASI Pharmaceuticals beats Theratechnologies on 8 of the 15 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
